Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Increased by Capital World Investors

Capital World Investors grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 408.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,025,301 shares of the life sciences company's stock after acquiring an additional 14,481,232 shares during the period. Capital World Investors owned about 11.37% of Illumina worth $2,408,721,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ILMN. Golden State Wealth Management LLC purchased a new stake in Illumina during the 4th quarter worth approximately $32,000. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina during the 4th quarter worth $45,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in shares of Illumina during the fourth quarter worth about $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

NASDAQ ILMN traded up $1.60 on Thursday, reaching $77.85. The company's stock had a trading volume of 702,494 shares, compared to its average volume of 2,270,469. The firm's 50 day moving average is $82.95 and its two-hundred day moving average is $119.06. The stock has a market cap of $12.32 billion, a PE ratio of -10.15, a PEG ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Piper Sandler increased their target price on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Citigroup lowered their target price on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Barclays lowered their price objective on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. Finally, Morgan Stanley cut their target price on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $138.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.